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A B S T R A C T
Immune checkpoint inhibitors (ICIs) have been incorporated in the treatment strategy of advanced non-small
cell lung cancer (NSCLC) in first- and second-line setting improving the prognosis of these patients. However, the
treatment landscape has been also drastically overturned with the advent of targeted therapies in oncogenic-
addicted advanced NSCLC patients. Despite ICIs represent an active and new treatment option for a wide range
of advanced NSCLC patients, the efficacy and the optimal place of ICI in the treatment strategy algorithm of
oncogenic-addicted tumors remains still controversial, as only a minority of trials with ICI enrol oncogenic-
addicted NSCLC patients previously treated with standard therapy. Therefore, there are still several open
questions about ICI in oncogenic-driven NSCLC, such as the efficacy and toxicities, which need to be addressed
before considering treatment with ICI as a standard approach in this population. It is in this framework, we
provide a thorough overview on this currently controversial topic.
Introduction
After decades of considering platinum-based chemotherapy as the
backbone of treatment for most patients with advanced non-small cell
lung cancer (NSCLC), the landscape has been drastically overturned
with the advent of targeted therapies and immunotherapy.
Several immune checkpoint inhibitors (ICI) are now considered a
new standard of care in lung cancer treatment and have had a dramatic
impact on patients outcomes reaching a 5-year overall survival (OS) of
16% [1]. Listed chronologically, nivolumab [2,3], pembrolizumab
(restricted to patients with PD-L1 expression (Tumour Proportion Score
[TPS]) of at least 1% on tumor cells) [4] and atezolizumab [5] were the
firsts ICIs approved in advanced NSCLC, based on their survival su-
periority over standard chemotherapy in second-line setting. Shortly
afterwards, on October 2016 and January 2017, the FDA and EMA
endorsed pembrolizumab in previously untreated patients with TPS
greater than or equal to 50%, replacing chemotherapy as the first-line
treatment of choice in this subgroup of advanced NSCLC patients [6–8].
On top of all, recent data has proven the advantage of new combination
strategies based on ICI and platinum-based chemotherapy in both non-
squamous [9,10] (with higher benefit among tumors with high TPS)
and squamous NSCLC (regardless of the TPS) [11]. But, looking beyond
advanced disease, the advantage in progression-free survival (PFS)
achieved with durvalumab consolidation in patients with locally ad-
vanced disease regardless of histology or PD-L1 expression [12], has
also stirred up excitement for the huge potential of immunotherapy in
earlier stages of the disease.
Despite immunotherapy represents an active and new treatment
option for a wide range of advanced NSCLC patients, the efficacy and
the optimal place of ICI in the treatment strategy algorithm of
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oncogenic-addicted tumors remains still controversial, as only a min-
ority of trials with ICI enrol oncogenic-addicted NSCLC patients, such as
EGFR or ALK, previously treated with standard therapy. No doubt
about, personalised approach with targeted agents has dramatically
improved patients’ health outcomes [13–15]. Although only targeted
therapies for genetic alterations of EGFR, ALK, BRAF and ROS-1 are
considered so far standard of care, there are many other additional
actionable genetic aberrations such as MET, HER2, RET or NTRK with
great potential for target inhibition [16], but despite personalised
treatment all patients eventually progress. Therefore, ICI as mono-
therapy or in combination would be interesting strategies in oncogenic-
driven NSCLC patients. However, there are still several questions, such
as the efficacy and toxicities, which need to be addressed before con-
sidering treatment with immunotherapy as a standard approach in this
population. It is in this framework, that we have seen the opportunity of
providing a thorough overview on this subject.
PD-L1 expression, Tumor Mutational Burden (TMB) and ICI
efficacy
We do now have plenty of data confirming the predictive, albeit
imperfect, ability of PD-L1 to identify NSCLC patients with most fa-
vourable outcomes to PD-(L)1-blockade [17–19]. Despite its con-
troversial results and constraints based on the responses observed in
some negative tumours, PD-L1 expression measured by im-
munohistochemistry is currently the main scaffold decision-making tool
used in clinical practice for selecting those patients deriving most
benefit from ICIs at least in first-line setting [19]. Other im-
munotherapy markers, specifically tumor-mutation burden (TMB) and
microsatellite instability (MSI) among others, are also emerging as
potentially helpful markers to predict response to ICI. Rational is based
on the observation that highly mutated tumors, such as NSCLC [20], are
more likely to retain neoantigens which are recognised as foreign by
activated immune cells [21–23]. TMB can be determined through
whole exome sequencing (WES) or targeted next generation sequencing
(NGS) and it is defined as either the total number of somatic mutations
in the tumor exome (WES) or the total number of synonymous and non-
synonymous mutations per megabase (Mb) present at ≥5% allele fre-
quency in the sequenced tumor genome by NGS (FoundationOne CDx
assay). TMB is particularly increased in smokers and noteworthy in
metastases as compared to primary counterparts [24,25]. Importantly,
TMB and PD-L1 expression appear to be independent predictors of re-
sponse to ICIs [21,24] as reflected in recent results of first-line phase 3
trials (Checkmate 026 and Checkmate 227) in which progression free
survival (PFS) was significantly improved either with nivolumab [26]
or nivolumab and ipilimumab [27] as compared to chemotherapy in
those patients with high TMB irrespective of PD-L1 expression levels.
However, there is still a long road ahead of us towards a proper stan-
dardization of TMB calculation and reporting. Indeed, the optimal
threshold for determining high TMB is still to be defined. In a discovery
set cohort of 64 NSCLC patients treated with ICI, a threshold of
TMB≥ 15 Mut/Mb significantly correlated with longer time on treat-
ment [28], but in the Check Mate 568 phase II trial, TMB≥ 10 Mut/Mb
was identified as the optimal cut-that correlated with ICI benefit [29].
Therefore, TMB should be prospectively validated in a large cohort. Of
note, oncogenic addicted tumors are usually correlated with a non- or
light-smoking habit, and a recent cohort of advanced NSCLC patients
reported no significant differences in PD-L1 expression but significant
higher TMB in smoker patients compared to light/never-smoker (8.5
Mut/Mb vs. 4.1 Mut/Mb, p=0.002), respectively, and TMB [30]. This
low TMB is especially significant among the oncogenic alterations
strongly related with never-smoker habit such as EGFR mutation and
ALK rearrangements [31]. However, it seems that TMB does not cor-
relate with response to ICI to in driver-mutated tumors, but it should be
prospectively validated [32]. Likewise, MSI, a pattern of hypermutation
that occurs due to defects in the mismatch repair system, has also been
identified as an independent predictor of response to immunotherapy
regardless of the cancers’ tissue of origin [33]. However, its rarity (only
a small fraction of 3.8% of cancers and 1% of NSCLC) [34], impairs its
use, at least in NSCLC, as an unique clinical ICI biomarker.
Unlike unselected NSCLC, data on ICI activity in patients with on-
cogenic addiction is much more limited. Recently, the ImmunoTarget
cohort [29] has gathered important data. In this multicentric world-
wide retrospective cohort, a large set of 551 advanced NSCLC patients
treated with ICIs and clustered by driver alterations (271 KRAS, 125
EGFR, 43 BRAF, 36 MET, 29 HER2, 23 ALK, 16 RET and 7 ROS1) were
evaluated for outcomes. ICI were mainly anti-PD1 (92%) given in the
first- (5%), second- (42%), third- (26%) or later treatment-lines (27%).
For those patients with PD-L1 expression available, 33% (71/214) and
67% (143/214) samples were PD-L1 negative and positive, respec-
tively. With a median follow-up of 16.1months, the outcomes with ICI
in the overall cohort reported response rates (RR) of 19%, median PFS
of 2.8 months and an OS of 13.3 months which was similar according to
smoking patterns and PD-L1 expression (Table 1). Taken together, this
data looks like an accurate replica of the outcomes observed in previous
trials with unselected and pre-treated NSCLC patients. However, on
closer inspection, it can be noticed that the magnitude of ICI benefit,
mainly regarding RR, among the different oncogenic subgroups was
distinctly different (Table 1). However, the limited number of patients
in some oncogenic alterations does not lead to obtain firm conclusions.
The variability of PD-L1 expression [35], the seldom overlaps with high
PD-L1 expression (≥50%) [36], the limited TMB and the low occur-
rence of smoking habits associated to some genomic alterations
[24,37,38] (Table 2), as well as differences in tumor microenvironment
between different oncogenic alterations and retrospective collection of
data may explain the discrepancy in the ICI efficacy in this population.
Of note, 57% of patients enrolled on ImmunoTarget cohort [35] had
progressive disease to ICI as best response. This percentage is sub-
stantially higher than that reported in unselected adenocarcinoma pa-
tients in pivotal trials (∼45%) [3–5], so, it is unknown whether on-
cogenic-driver tumors could be at higher risk of developing hyper-
progressive disease on ICI, a phenomenon otherwise reported in 14% of
unselected NSCLC patients [39].
In another smaller cohort of 52 never or light-smoking NSCLC pa-
tients (21% KRAS, 12% EGFR, 7% BRAF, and RET/HER2/MET, each
4%), with high PD-L1 expression (≥50% by E1L3N), all treated with
anti-PD(L)1 in first- (63%), second- (21%) or ≥third-line (15%), the
efficacy measured by RR was 26% with a median duration of response
(DoR) of 5.6 months and median PFS and OS of 3.0 and 16.4 months,
respectively [30]. Currently, ongoing clinical trials are exploring the
use of combination strategies (tyrosine kinase inhibitors or che-
motherapy and ICI) in oncogenic-addicted NSCLC patients. However,
careful considerations must be made given the increased risk of toxicity
described with the use of both concomitant and sequential combina-
tions of targeted agents and ICIs [40].
Table 1
Outcomes with ICIs in oncogenic addicted NSCLC patients (ImmunoTarget
Cohort [35]).
Genomic alteration N RR (%) PFS* (mo) OS* (mo)
BRAF 43 24 3.1 13.6
KRAS 271 26 3.2 13.5
ROS1 7 17 NA NA
MET 36 16 3.4 18.4
EGFR 125 12 2.1 10
HER2 29 7 2.5 20.3
RET 16 6 2.1 21.3
ALK 23 0 2.5 17.0
RR: response rate. N: number. PFS: Progression free survival. OS: Overall
Survival.
* From ICI initiation.
J. Remon et al. Cancer Treatment Reviews 71 (2018) 47–58
48
KRAS mutation
KRAS mutation is the most common oncogenic alteration found in
lung cancer with an incidence of approximately 30% in adenocarci-
nomas [41]. KRAS-mutations are ethnic-driven since they are found in
only 10% of Asian patients [42] and have a close link with tobacco
exposure with an incidence ranging between 25 and 35% in ever
smokers and only 5% in non-smokers. In lung adenocarcinoma, most
common KRAS-mutations occur in codons 12 and 13, being G12C
transversion among the most commonly mutation reported in ap-
proximately 40% of the cases. The fact that no targeted therapy has yet
been approved for the treatment of KRAS-mutant NSCLC [43] and its
strong relation with cigarette smoking, awoke the plausible interest to
deeper explore the use of ICI in this subgroup of patients.
PD-L1 expression is significantly increased in KRAS-mutant tumors
as compared to wild-type counterparts (38.9% versus 16.2%,
p < 0.001) as well as in KRAS- G12V variants as compared to other
KRAS-mutations (8% for G12C, 5.3% G12D and 12.9% G12V,
p= 0.044) [44], with high PD-L1 expression (≥50%) in 17% of KRAS-
mutant patients [45]. Furthermore, median TMB is also higher in KRAS-
mutant than unselected adenocarcinoma tumors (9.0 mut/Mb com-
pared with 6.3 Mut/Mb) [46]. Despite the unambiguous association
with smoking, the immediate impact of KRAS-mutation on the effec-
tiveness of ICI in lung adenocarcinomas is more than debatable. In a
recent systematic review and meta-analysis of 5 clinical trials involving
3,025 NSCLC patients treated in second line with ICI (nivolumab,
pembrolizumab, atezolizumab) [47] although a greater benefit with a
35% reduction in the risk of death was observed in KRAS-mutant
NSCLC patients (HR, 0.65; 95% CI, 0.44–0.97; p=0.03) as compared
to KRAS wild-type (HR, 0.86; 95% CI, 0.67–1.11; p=0.24), no statis-
tically significant test interaction differences were noted between KRAS
status and treatment effect (P=0.24). Hence, the use of KRAS-muta-
tion as the sole predictive biomarker for the selection of patients for ICI
therapy appears unreasonable. On the contrary, the coexistence of both
high PD-L1 expression and KRAS-mutation, has been significantly as-
sociated with an improved OS (p=0.012), an advantage otherwise not
reproduced in the wild-type population (p= 0.385) in this study [44].
Among the 271 KRAS-mutant NSCLC patients enrolled in the Im-
munoTarget cohort, ICIs reported RR of 26%, with a median PFS of
3.2 months and OS of 13.5months (Table 1). Whereas the levels of PD-
L1 expression significantly correlated with an improved PFS (p= 0.01),
neither the type of KRAS-variant (p= 0.47), nor the number of pre-
vious lines received (p=0.66) had an impact on outcomes [35].
Besides PD-L1 expression, data gathered over recent years has
identified distinct molecular features of KRAS-mutant tumors co-oc-
curring with other mutations such as the tumor suppressor gene serine/
threonine kinase 11 gene (STK11) also known as liver protein kinase B1
(LKB1) [48]. The STK11 is mutated in approximately 15 to 20% of
NSCLC and STK11/LKB1 function is lost in approximately one-third
[49] to 50% [48] of KRAS-mutant adenocarcinomas. STK11 mutations
correlate with smoking history [48,49] and, though its prognostic role
is still uncertain, it seems that STK11 loss-of-function might correlate
with worse outcomes in advanced NSCLC [48]. Indeed, co-existence of
both mutations (KRAS-driven, LKB1-deficient) is associated with a
higher number of metastatic sites at diagnosis as well as an increased
risk for developing brain metastases [49]. This observation might ex-
plain the trend toward a detrimental effect on OS described with the
concurrence of both mutations [48,49].
Interestingly, inactivation of STK11 (or its protein product, LKB1)
by mutational or non-mutational mechanisms has been associated with
an inert or “cold” tumor immune-microenvironment [50]. This ob-
servation has also been observed in pre-clinical models, in which
STK11/LKB1-positive lung adenocarcinoma cell lines are characterized
by a low TPS as well as a decrease in the percentage of tumor-in-
filtrating lymphocytes (TILs) [51]. Accordingly, the co-existence of
STK11 alterations in KRAS-mutant lung adenocarcinoma patients
treated with PD-1 inhibitors correlates with lower RR (28.6% vs. 7.4%,
p < 0.001), shorter PFS (p < 0.001) and worse OS (p= 0.0015) [51],
suggesting its nature as a major genomic driver for primary resistance
to ICI therapy. Moreover, STK11/LKB1 de novo resistance to PD-1/PD-
L1 inhibitors is retained even among those PD-L1-positive NSCLC pa-
tients, suggesting that their effect is at least partially independent of
PD-L1 expression. Therefore, genomic screening evaluation of STK11/
LKB1 might be useful to enhance the predictive utility of a composite
ICI-predictive biomarker panel, together with PD-L1 expression and
TMB [52]
EGFR mutation
EGFR mutation is the most common druggable genomic alteration
reaching 15% of lung adenocarcinomas in the Caucasian population
and in up to 60% of the Asian population. EGFR-mutations are more
common in never/light smokers and females. First- and second-gen-
eration EGFR tyrosine kinase inhibitors (TKI) -erlotinib, gefitinib, and
afatinib-, as well as third-generation EGFR TKI -osimertinib- are ap-
proved as upfront standard treatments for tumours with common sen-
sitizing EGFR-mutations [53,54]. Osimertinib has also been approved
for the 60% of patients who develop an acquired resistance T790M
mutation [55]. Platinum and pemetrexed combination remains the
standard of care for those patients without the T790M at TKI-progres-
sion [56].
There is plenty of evidence that EGFR-driven lung tumors drive
immune escape by upregulating PD-1, PD-L1, CTL antigen-4 (CTLA-4),
and other tumor-promoting inflammatory cytokines and PD-L1 ex-
pression can be reduced by EGFR-inhibition in EGFR-mutant NSCLC cell
lines [57]. However, although PD-L1 expression is higher in EGFR-
mutant cell lines compared with wild-type counterparts [58] results in
the clinic are thus far conflicting with variable expression levels re-
ported in literature, mainly in pre-treated patients. Some recent retro-
spective analysis have reported lower PD-L1 expression scores in pre-
treated EGFR-mutant patients, compared to EGFR-wild-type [59],
however, contradictory results have been reported in two different
meta-analyses [60,61]. It is worth mentioning that there was a huge
variety of PD-L1 assays and antibody clones used, challenging its ex-
trapolation of preclinical data into clinical practice. Recently, clinical
data from the prospective FLAURA phase III clinical trial in untreated
EGFR-mutant patients has reported that PD-L1 expression is less
common in EGFR-mutant than EGFR-wild type samples, particularly in
higher thresholds (PD-L1≥ 25%: 8% vs. 35%; and PD-L1≥ 50%: 5%
vs. 28%) [62]. Despite that some retrospective clinical cohorts in EGFR-
Table 2
PD-L1 expression and TMB biomarkers among different driver alterations in
NSCLC.
Genomic
alteration
PD-L1 ≥50%
(%)
TMB
(median Mt/Mb)
Non-selected 35% 5.7–7.4
KRAS 17% 9.0
BRAF 45%
(V600-E > non-
V600E)
High TMB (≥20Mb) in V600-E vs.
non-V600E: 20% vs. 0%
MET 44% 3.8–4.5
EGFR 33% to 57.1%
(heavily pre-treated)
3.8
(3.6 Mut/Mb for EGFR exon 19
deletions, 3.8 for L858R and 4.5 for
T790M)
HER2 13% 5.7
ALK 26% crizo-naíve
17% crizo-resistant
3.1
ROS1 5% (1/19) 3.6
RET 21% 3.3
TMB: Tumor Mutational Burden; Mt: mutations; Mb: Megabase; Crizo: crizo-
tinib.
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mutant population have correlated the PD-L1 expression with de-
creased EGFR TKI efficacy [63], in the FLAURA trial, the PFS benefit
with osimertinib compared to standard treatment occurs regardless of
PD-L1 status [62]. Other series have suggested the dynamic increase of
PD-L1 expression over time [45]. Indeed, PD-L1 expression of≥1% and
≥50% has been reported in only 24% and 11% of pre-treated EGFR-
mutant patients [45], rates otherwise much lower that of reported in
unselected NSCLC patients (PD-L1≥ 1%, ≥50% in 60% and 35% of
samples respectively) [4]. On the other hand, although high TPS of at
least 50% seldom overlaps with driver genes in untreated EGFR-mutant
tumours [36] in heavily pre-treated patients higher levels of PD-L1
(≥50%) have been reported in around 33% of patients (18 of 54) [64].
This phenomenon underlines the dynamic nature of PD-L1 expression
in EGFR-driven tumors and sustains the increased infiltration of CD8
TILs observed within the tumor microenvironment at the onset of re-
sistance [45]. T790M-mutation, on the other hand, seems to be corre-
lated to lower PD-L1 expression levels compared to T790M-negative
resistant tumors (31% vs. 61%, p=0.0149) [65]. The TMB, as happens
in other driven-tumors, is significantly lower than in unselected NSCLC
patients (3.8 vs. 6.12 Mut/Mb, respectively, p < 0.0001) [66] and it
does not appear to be major different according to EGFR-mutation
subtypes (3.6 Mut/Mb for EGFR exon 19 deletions, 3.8 for L858R and
4.5 for T790M) [46]. Of note, TMB increases at resistance time (median
6.56 vs. 3.42 Mut/Mb, p=0.008), and TMB is negatively associated
with clinical outcome in EGFR-mutant NSCLC patients treated with
EGFR TKI [66].
Despite the variable PD-L1 expression and low TMB, several im-
munotherapeutic approaches have been tested in EGFR-mutant patients
based on the enhanced susceptibility to immune-checkpoint blockade
observed in EGFR-mutant mouse models [57], although no signs of
synergistic efficacy were noted in co-cultures with combination stra-
tegies of EGFR-TKIs and ICIs [67].
In a phase II trial in EGFR TKI naïve, PD-L1 positive (≥1%, 22C3
antibody) EGFR-mutant NSCLC patients, no signs of activity were re-
ported with pembrolizumab, including those with PD-L1 expression
≥50%, suggesting that first-line treatment with ICI in this subgroup of
oncogenic tumors is far less than appropriate. Indeed, three out of the
seven patients that were subsequently treated with EGFR-TKI experi-
enced grade 3–5 toxicity [68], underlying the potential increased risk of
toxicity when combination approaches are performed, even in a se-
quential manner. Likewise, in second-line setting a meta-analysis re-
ported the lack of OS benefit with ICIs in this population (HR 1.11; 95%
CI 0.80–1.53, p= 0.54, interaction p=0.005) [69]. However, some
signs of activity have been reported in some other retrospective studies.
Among the 125 EGFR-mutant NSCLC patients enrolled in Im-
munoTarget cohort, ICIs reported RR of 12%, with a median PFS and
OS of 2.1 months and 10months, respectively (Table 1). Whereas the
levels of PD-L1 expression significantly correlated with an improved
PFS (p=0.01), neither the type of EGFR-mutation subtype (p= 0.35),
nor the number of previous lines received (p=0.19) had an impact on
PFS [35]. In another retrospective Italian cohort enrolling 102 EGFR-
mutant NSCLC patients treated with nivolumab, the RR was lower in
EGFR-mutant patients compared to wild-type patients (RR 8.8% versus
19.6%, p=0.007) but no differences in PFS and OS were observed
[70]. The phase II ATLANTIC trial testing durvalumab as third-line
treatment included the largest cohort of EGFR-mutant patients treated
with ICI (n= 98) after progression on EGFR TKI and chemotherapy.
According to PD-L1 expression (< 25% or ≥25%), durvalumab
achieved a RR of 3.6% and 14.1%, a similar median PFS 1.9months and
a median OS of 9.9months and 13.3months, respectively [71,72].
Some other clinical trials (CheckMate 012 [73], CA209-003 [1],
CA209-153 [74], KEYNOTE 001 [64] and BIRCH trials [75]) have also
enrolled representative cohorts of EGFR-mutant NSCLC patients and the
efficacy ICI in this population is summarized in the table 3.
On the other hand, data on the activity of ICI in patients with non-
classic EGFR-mutations is scarce. Compared to classic EGFR-mutations,
patients with non-T790M exon 20 mutations seem to gain better PFS
and OS when treated with ICI (2.9 vs. 1.9 months, HR 0.45, p= 0.002
and NR vs. 11.5months, HR 0.2, p < 0.001) [76]. However, the lim-
ited number of patients included does not lead to obtain firm conclu-
sions.
Despite lack of synergism reported in preclinical models with EGFR
TKI and ICI [67], several early phase clinical trials have evaluated this
strategy. Design, primary outcome, results and toxicity (≥grade 3) are
summarized in table 4. As expected, in TKI naïve patients, ORR was
70–79%, which is comparable to that obtained with EGFR-targeted
therapy alone in first-line. Likewise, as foreseen by preclinical results,
no clear synergistic effect of the combination was observed (Fig. 1).
Grade≥ 3 AE’s were common (24–54%) and variable (table 4 and
Fig. 1). Of note, the IMPOWER 150, a phase III trial testing the com-
bination of bevacizumab plus carboplatin-paclitaxel with or without
atezolizumab in first-line setting, enrolled 70 EGFR-mutant TKI-pre-
viously-treated advanced NSCLC patients. In the EGFR/ALK subgroup
the combination arm with atezolizumab significantly improved the PFS
compared to control arm, (9.7 vs. 6.1months, HR 0.59 [0.37–0.94]) as
well as OS (not reached vs. 17.5 months, HR 0.54 [0.29–1.03]) but
carboplatin-paclitaxel with atezolizumab did not improve OS over
control arm (21.2 vs. 17.5months, HR 0.82 [0.49–1.37]) in this po-
pulation [10].
Other intervention strategies are to evaluate the combination of ICIs
plus chemotherapy in the resistant setting (NCT02864251,
NCT03256136, NCT03515837), as well as the combination of ICI and
anti-CD73 therapies (NCT03454451) based on preclinical rational sus-
taining CD73 expression as a biomarker of immune-resistance.
Nonetheless, the definitive place of immunotherapy in the therapeutic
landscape of EGFR-mutant patients remains to be defined.
BRAF mutation
BRAF mutations are observed in 1% to 2% of lung adenocarcinomas
[41,77,78], preferentially in non-mucinous mainly micro-papillary
adenocarcinomas, although cases have also been reported in sarcoma-
toid and large cell carcinomas. Unlike melanoma, only half of BRAF-
mutations found in NSCLC are V600E. Most common clinical features
include female gender [79] and smoking habits [80], and outcomes
trend to be poorer [81] with lower responses to chemotherapy [41,82].
BRAF V600E mutations predict response to BRAF-inhibitors such as
vemurafenib or dabrafenib [83,84], as well as double BRAF-MEK in-
hibition with dabrafenib and trametinib [85,86], so BRAF-mutation
screening is currently recommended in clinical practice [16]. Based on
the results of the single arm phase II trial with dabrafenib and trame-
tinib combination in first-line setting (RR of 64% and median PFS and
OS of 10.9 and 24.6 months, respectively), both the FDA and EMA have
endorsed double BRAF-MEK inhibition combination as standard treat-
ment in BRAF-V600E mutant advanced NSCLC patients [84].
As BRAF-mutation is associated with smoking history, the efficacy
of ICI in this subpopulation merits undeniably further evaluation. In a
recent retrospective cohort of 39 BRAF-mutant advanced NSCLC pa-
tients (21 V600E- and 18 non-V600E), high PD-L1 expression levels
(≥50% by 22C3 IHQ) were reported in ∼45% of patients, with is
otherwise higher than that reported in unselected NSCLC patients. In
BRAF (V600E) tumors, 25% of cases were associated with high TMB
(≥20Mb, by FoundationOne algorithm) compared with 0% in non-
V600E mutant tumors; and all cases were microsatellite stable regard-
less of BRAF-mutation subtype [87]. In another series, median TMB was
higher in BRAF non-V600E than in V600E, 10.8 Mut/Mb compared with
3.8 Mut/Mb, respectively [46]. Among patients treated with ICIs
(N= 22), there were 28% of responses, with a median PFS of
3.7 months and an OS that has still to be reached. Any of the outcome
measures (RR, PFS or OS) were found to be significantly correlated with
BRAF-mutation subtype or PD-L1 expression [87]. However, those pa-
tients who received ICIs lived significantly longer than those not
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exposed to ICI (non-reached vs. 21.1months, p= 0.018) [87]. The re-
sults mirror those reported in the ImmunoTarget BRAF-mutant cohort
(n=43) with 24% RR and a median PFS and OS of 3.1 and
13.6 months, respectively (Table 1). In this study, neither BRAF-muta-
tion subtype nor the number of previous lines impacted PFS, but rather
smoking habits, while no data on the correlation with PD-L1 expression
was provided [35].
In view of these results, ICI may play indeed a role in the ther-
apeutic landscape of BRAF-mutant NSCLC patients regardless of pre-
dictive biomarkers and BRAF-mutation subtype. It remains unknown
though, whether combining immunotherapy and double BRAF-MEK
inhibition might improve outcomes considering the high response rates
of targeted therapy and the durability of responses obtained with im-
munotherapy. It is nevertheless important to note, that improved anti-
tumor activity of immunotherapy with BRAF and MEK inhibitors has
been already described using syngeneic BRAF(V600E)-driven mouse
models in melanoma [88].
MET mutation
The mesenchymal epithelial transition factor receptor (MET) gene is
located on chromosome 7q21–q31 and its oncogenic function in lung
cancer, occurs through its dysregulation via a variety of mechanisms,
including gene mutations (mainly occurring in exon 14 [ex14]) or
amplification (both reported in 3% of lung adenocarcinomas), re-
arrangements, and protein overexpression [89–91]. MET ex14 splicing
mutations are common in older patients and more likely associated
with smoking compared to other oncogenes [92], and is found enriched
up to 22% in sarcomatoid histologies [93]. Although both MET ex14
splicing mutation and MET amplification, predict worse survival [91],
they promote sensitivity to MET-inhibitors with RR about 40% in pa-
tients treated with crizotinib [94,95]. Based on the results, the FDA
Table 3
Clinical outcome of EGFR-mutant tumors treated with immune checkpoint inhibitors in clinical trials enrolling non-small cell lung cancer patients.
Author/Trial PD-L1
restricted?
Treatment Total r of ICI
patients*
EGFR wt/
EGFR +
ORR (%) for ICIEGFR− vs
EGFR+
DoR in months
for ICI EGFR− vs
EGFR+
Median PFS in
months for ICI
EGFR− vs
EGFR+
Median OS in
months for ICI
EGFR− vs
EGFR+
Remarks (tox, LTS)
EGFR TKI naive trials
Lisberg [130] TPS ≥1% Pembro All EGFR+
11 (1 false
positive)
False positive: response,
EGFR+0
False positive: 8.2
EGFR no
responses
NA NA Subsequent TKI: 3/7
patients TRAE gr
3–5
EGFR TKI pretreated/no specific requirements regarding TKI pretreatment trials
CheckMate 012∼
[73]
Unselected
patients
Nivo 52
31/8
30/14 NR 6.6 vs 1.8 NA –
CheckMate 012ß
[131]
Unselected
patients
Nivo+ ipi 78
54/8
41/50 NA EGFR− NA
EGFR+ 13.6
NA –
CA209-003
[1]
Unselected
patients
Nivo 129
56/13
19.6/16.7 NA NA NA 16 survivors
≥5 years
2 EGFR+ (exon 20
ins and exon 18
G719A)
CA209-153
[74]
Unselected
patients
Nivo 129/12 17/16Δ NA NA NA –
CheckMate 057 [3] Unselected
patients
Nivo 292
168/44
18/11 NA For EGFR+: HR
1.46 ICI vs
chemo
For EGFR+: HR
1.18 ICI vs
chemo
–
KEYNOTE 001
[64]
Unselected
patients
Pembro 550
450/77
21.6/7.8 NA NA NA –
KEYNOTE 010 [4] TPS≥ 1% Pembro 690
581/60
NA NA For EGFR+: HR
1.79 ICI vs
chemo
For EGFR+: HR
0.88 ICI vs
chemo
–
BIRCH∑ [75] TC/IC≥ 5% Atezo 659
498/45
19/9 NR vs 8.5 5.5 vs 5.5 NR vs 20.1 –
OAK [5,132] Unselected
patients
Atezo 425
318/42
15/5 NA NA 15.3 vs 10.5
For EGFR+: HR
ICI vs chemo
1.24
9% of LTS
(≥24months
survival) was
EGFR+
ATLANTIC [71,72] After amend-
ment
TPS≥ 25%
Durva Cohort 1:
11115 ALK/
97 EGFR∞
ALK:0
EGFR:
TPS < 25/TPS≥ 25%
3.6/14.1
ALK: no
responses
EGFR+7.4
Cohort 1: 1.9 Cohort 1:
9.9–13.3
–
Large retrospective series
Italian EAP [70] Unselected
patients
Nivo 1588
1293/102
19.6/8.8 NA 3.0 vs 3.0 (HR
1.38)
11.0 vs 8.3 (HR
1.11)
–
Mazieres, 2018
ImmunoTarget
[35]
Unselected
patients
All ICI 550
NA/125
Total 19.0/EGFR 12.0 NA Total 2.8
EGFR 2.1
Total 13.3
EGFR 10.0
–
Abbreviations: PD-L1: programmed death ligand1; nr: number; ICI: immune checkpoint inhibitor; EGFR: epidermal growth factor receptor; wt: wildtype; DoR:
duration of response; vs: versus; PFS: progression free survival; OS: overall survival; tox: toxicity; LTS: long term survival; TKI: tyrosine kinase inhibitor; TPS: tumor
proportion score; pembro: pembrolizumab; NA: not available; TRAE: treatment related adverse events; nivo: nivolumab; NR: not reported; ipi: ipilimumab; ins:
insertion; chemo: chemotherapy; TC: tumor cells; IC: immune cells; atezo: atezolizumab; durva: durvalumab; ALK: anaplastic lymphoma kinase; EAP: expanded
access program
* Also including EGFR unknown; ∼:7/8 EGFR-mutant patients EGFR TKI pretreated; ß:7 patients received previous erlotinib, 4 other targeted therapies, not
specified according to EGFR-mutational status; Δ: only responses at first assessment mentioned; ∑: results cohort 1 summarized for DoR, PFS and OS as pooling was
not possible; ∞: 1 patient both EGFR and ALK+.
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approved on May 2018, the use of crizotinib for the treatment of MET-
mutant NSCLC patients.
Recent data provides more insights about the immunophenotype of
MET-driven NSCLC. In preclinical models, MET-signalling activation
promotes a transcriptional increase of several negative checkpoint
regulators of the immune-response such as PD-L1, suggesting that an
immunosuppressive environment is one of the oncogenic features of
MET [51]. Expression of PD-L1 in MET ex14 NSCLC tumor samples is
frequent, with almost 44% of tumours expressing levels ≥50% (by
E1L3N clone), but unlike in the unselected population, median TMB is
significantly lower (5.7 vs. 3.8 Mut/Mb, p= 0.0006) [38,46]. In a small
cohort of 63 patients with MET ex14 skipping NSCLC, time on therapy
with ICIs ranged from 2weeks to 9.6+months and overall RR was
13%, though somehow increased in those patients with higher levels of
PD-L1≥ 50% (33% vs. 20% in patients with PD-L1 0%, respectively)
[38]. These results mirror those reported in ImmunoTarget cohort
among 36MET ex14 skipping NSCLC (42% PD-L1 positive) with a RR of
16% and median PFS and OS of 3.4months and 18.4months, respec-
tively [35].
As such, it is evident that despite frequent PD-L1 expression, re-
sponses to immunotherapy in MET ex14 NSCLC patients are globally
uncommon and lower than that observed with targeted therapy. There
is, therefore, a clear need for further exploration to unveil the under-
lying mechanisms of immunotherapy resistance in this defined subset of
PD-L1 expressing tumors.
HER2
HER2 alterations, including HER2 mutations and HER2 amplifica-
tions are found in approximately 2–6% and 2–5% of lung adenocarci-
nomas, respectively. In addition, high level (3+) HER2 protein over-
expression by IHC occurs in 2–4% of lung cancers. HER2 mutations are
not associated with HER2 amplification, thus representing distinct
clinical entities and therapeutic targets [96]. HER2-mutations are more
common in adenocarcinoma, women and non-smoker population [97],
in contrast to HER2 amplifications which are more common in male and
former smokers [96]. The ado-Trastuzumab emtansine (T-DM1), is an
antibody-drug conjugate that has showed preliminary promising ac-
tivity in HER2-mutant lung tumours but otherwise unsatisfactory for
patients with HER2-positive lung cancer [98]. As no personalised tar-
geted therapy has yet been approved, chemotherapy remains for the
time being the core treatment option in this population of lung cancer
patients [99].
The landscape of PD-L1 and TMB in this subset of lung cancers as
well as their sensitivity to ICI is largely unknown. Recently, PD-L1 ex-
pression (E1L3N clone) and TMB (by NGS) has been studied in a large
cohort of 122 HER2-mutant NSCLC patients. Notable among these, PD-
L1 expression levels were lower (only 13% of patients had PD-
L1≥ 50% and 77% of samples with PD-L1 < 1%) but TMB was similar
to unselected lung cancers (median TMB 5.7 Mut/Mb) [100]. Among 26
HER2-mutant patients who received ICIs, RR was uncommon with only
12% (including 3 partial responses, two of them reporting high PD-
L1≥ 50% and TMB above the median). The median PFS and OS were
also poor; 1.9months and 10.4 months, respectively [100]. In 29 HER2-
positive NSCLC patients enrolled in ImmunoTarget cohort, outcomes
were consistently poor (RR 7% and PFS and OS of 2.5 and 20.3months
respectively), but they did not gather data regarding expression level of
PD-L1 (27% PD-L1-posiitve) or TMB [35] (Table 1).
Although activity of ICI seems to be poor in patients with HER2-
altered lung cancers, treatment with ICI might be still be considered,
particularly in the context of high PD-L1 expression or TMB. However,
it is advised that data on ICI activity here reported is based only on
small series of patients, so larger-scale validations are needed to sustain
these observations.
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ALK rearrangements
ALK rearrangements result from inversions or translocations on
chromosome 2 and are present in ∼5% of NSCLC tumours [41,77]. Its
phenotype is not linked to any ethnic group, but it is more commonly
found in never/light smokers, young patients and adenocarcinoma
subtype with either signet-ring or acinar pattern. This population ex-
periences a remarkably long OS, up to 7.5 years, when sequential ALK
inhibitors are prescribed [101]. Based on the positive results of dif-
ferent phase III clinical trials, several ALK inhibitors have been already
approved in first-line setting by both EMA and FDA (crizotinib ac-
cording to PROFILE 1014 trial [102,103], ceritinib based on the AS-
CEND 4 trial [104], and alectinib based on the ALEX trial [105,106]). In
first-line setting, ALK inhibitors have outstanding activity with overall
RR ranging from 73% to 83%, median DoR from 11.3 to 33.3months,
PFS of 10.9months to 34.8 months and variable toxicity (grade≥ 3
adverse events [AE’s] 45% to 78%). In crizotinib-refractory ALK-posi-
tive NSCLC patients, several inhibitors have also shown to retain no-
table activity; among them ceritinib (ASCEND 5 phase III trial [107]),
alectinib (NP28673 and NP28761 phase II trials [108]), brigatinib
(ALTA phase II trial [109,110]), ensartinib [111], and lorlatinib in a
phase II trial [112]. Currently ceritinib, alectinib (FDA and EMA) and
brigatinib (FDA) have been granted market authorization in crizotinib-
refractory patients.
As observed in other driver alterations, PD-L1 expression is re-
markably increased with over-expression of ALK fusion protein [58].
TPS scored as ≥1%, ≥ 5%, and ≥50% is found in 63%, 47% and 26%
ALK-naïve tumor samples (N= 19), and in 42%, 25% and 17% in ALK-
resistant biopsies (N=12) [45]. and PD-L1 TPS score ≥50% can reach
57.1% in heavily pretreated ALK samples [64]. However, TMB in this
population is significantly lower (mean 3.1 mutation/Mb) than found in
unselected NSCLC patients [28].
In vitro, PD-L1 mediated by ALK fusion protein induces apoptosis of
T cells and treatment with ALK inhibitors can reduce PD-L1 expression
and reverse T cell suppression [113]. Although in co-culture models, ICI
is effective in both crizotinib-sensitive and -resistant ALK-positive cell
lines, no synergistic tumor killing effects are observed by combining
ALK inhibitors and ICI, probably due to the enhanced antitumor im-
munity induced by ALK inhibitors via the downregulation of PD-L1
[113]. Notwithstanding, preliminary data of ICI efficacy in ALK-
positive NSCLC patients included in prospective trials (ATLANTIC)
[71], as well as in retrospective cohorts of patients [45], such as the
ImmunoTarget cohort [35], (Table 1) is deeply discouraging, with no
responses observed, calling into question the role of ICI in these subset
of oncogenic tumors. In the previously reported IMPOWER 150 phase
III trial, 34 ALK-positive previously treated advanced NSCLC patients
were enrolled. In the EGFR/ALK cohort, PFS and OS was longer in the
combination arm with atezolizumab compared with the control arm
[10], so this combination could be a potential therapeutic strategy in
selected ALK-positive NSCLC patients who have become refractory to
all ALK inhibitors available.
The next step was therefore to explore new combinations of targeted
therapy with immunotherapy with the hypothesis that this approach
could result in more responses and/or more durable responses in ALK-
positive patients (Table 5). The phase Ib JAVELIN Lung 101 trial
evaluated the combination of avelumab (10mg/kg Q2W) and lorlatinib
(100mg QD) in previously treated ALK-positive patients (n= 28), as
well as the combination of avelumab (at the same dose) plus crizotinib
(250mg BID) in ALK-negative NSCLC patients (n=12). The primary
endpoint was dose-limiting toxicities (DLTs); secondary endpoints in-
cluded AEs and ORR. In the ALK-positive cohort asymptomatic and
untreated brain metastases were allowed (36%) and most patients
020406080100
Checkmate 370
Javelin Lung 101
NCT02013219
NCT02393625*
NCT02393625¥
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NCT02088112
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GEFTREM
expected gr ≥3 TRAE mono TKI expected gr ≥3 TRAE mono IO actual trial gr ≥3 TRAE 
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expected RR mono TKI expected RR mono IO actual trial RR
0% 
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¥ TKI: pretreated; *: TKI naive 
Ref. 
[116] 
[115] 
[118] 
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[138] 
[137] 
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Fig. 1. Toxicity and efficacy (response rate) in EGFR-mutant and ALK-positive NSCLC patients treated with TKI with and without immunotherapy. Monotherapy data
RR: gefitinib: Paz-Ares Ann Oncol 2017; tremelimumab: Maio Lancet Oncol 2017; erlotinib: Rosell Lancet Oncol 2012; atezolizumab EGFR: Rittmeyer Lancet 2017;
erlotinib TKI pretreated: Capuzzo Lung Cancer 2017; nivolumab EGFR: Borghaei NEJM 2015; durvalumab EGFR: Garassino Lancet Oncol 2018; osimertinib: Soria
NEJM 2018; ceritinib: Shaw Lancet Oncol 2017; nivolumab ALK+: Mazieres ASCO 2018; alectinib: Peters NEJM 2018; atezolizumab ALK+: Mazieres ASCO 2018
(no specific atezolizumab data available for ALK); lorlatinib: Solomon WCLC 2017 data exp4 and 5 combined; avelumab ALK+: Mazieres ASCO 2018. Monotherapy
data gr ≥3 TRAE: same studies as for RR, except when AE instead of TRAE where reported in these studies, then replaced by studies with TRAE available: ceritinib:
Soria Lancet 2017; crizotinib Blackhall ESMO open 2017. All cause AE instead of TRAE (TRAE not availabe: ceritinib and alectinib monotherapy, Javelin Lung,
NCT02393625.
Table 5
Efficacy of ALK TKI in combination with immune checkpoint inhibitors in
treatment naïve or refractory NSCLC patients.
Javelin
Lung 101
Avelumab
Lorlatinib
[114]
Alectinib
Atezolizumab
[117]
CheckMate 370
Crizotinib
Nivolumab
[115]
Ceritinib
Nivolumab
[116]
N 28 21 13 16 20
Line Pre-treated Naïve Naive Naïve Pre-treated
RR (%) 46.4 86 38 68.8 35
DoR (mo.) 7.4 20.3 NR 14.9 11.9
PFS (mo.) NR 21.7 NR 16.6 4.6
AEs Gr≥ 3
(%)
56.4 57.1 62 83
PFS: Progression free survival. OS: Overall Survival. RR: response rate. N:
number. DoR: duration of response. AEs: Adverse Events.
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(71.4%) were heavily pretreated with ≥2 previous ALK inhibitors. No
data about PD-L1 expression in any of both cohorts were reported. The
RR and the DoR were 46.4% and 7.4 months in the ALK-positive cohort
and 16.7% and 4.1 months in the ALK-negative cohort, respectively.
The toxicity of the combination was significant and comparable in both
cohorts, with grade ≥3 AE’s in the range between 54 and 58% [114].
Due to the dismal outcomes and the high rate of AE’s, further devel-
opment of this combination in the ALK-negative cohort was withheld,
and although in heavily pretreated ALK-positive NSCLC patients the
combination seems to be active, the outcomes achieved did not differ
much from the ones observed with lorlatinib monotherapy (RR 39%,
median DoR 7months in previously pre-treated ALK-positive NSCLC
patients) [112] but with the drawback of higher toxicity.
But, toxicity concerns have also arisen with the use of other com-
binations. The phase I CheckMate 370 trial evaluated in a single arm-
cohort (group E) the safety of nivolumab (240mg Q2W) plus crizotinib
(250mg twice daily) in TKI-naïve ALK-positive patients [115]. The
enrolment was early terminated, as the primary endpoint (20% treat-
ment discontinuations due to treatment-related AEs by week 17) was
not met in the first planned safety review. Eight patients (62%) de-
veloped grade ≥3 AE’s including five patients (38%) who developed
severe hepatic toxicities with two possible related deaths. The rates of
discontinuations due to liver toxicity reported in this trial greatly ex-
ceed those reported with nivolumab (0.3–1.5%) or crizotinib (2.3%) as
monotherapy suggesting either a toxicity overlap or a synergistic result
of the combination [115].
In another phase I trial, TKI-naïve (n=16) and previously treated
(n=20) ALK-positive NSCLC patients, received nivolumab 3mg/kg IV
Q2W plus ceritinib with low-fat meal, at 450mg/day (group 1) or
300mg/day (group 2) [116]. The RR, DoR and PFS were of 69%,
14.9 months and 16.6 months among treatment-naïve patients and
35%, 11.9 months and 4.6 months, in previously treated patients. Once
again, grade ≥3 AE’s were commonly reported in 83% of cases, leading
to dose interruption and discontinuation in 64% and 22% of patients
respectively. Hepatotoxicity was the most common AE (all grades 69%
and grade 3 elevation of ALT 25%) and grade ≥3 rash occurred in 19%
of patients [116]. The preliminary efficacy results led to an amendment
to address observed toxicities and to further evaluate an alternative
dosing regimen with an induction period of ceritinib monotherapy
followed by the combination. Despite the activity of the combination, it
is worth highlighting that the results did not improve the outcomes
achieved with ceritinib monotherapy, neither in first-line [104] nor in
crizotinib-refractory patients [107], yet with a detrimental tolerability.
Lastly, the combination of alectinib and atezolizumab has been also
studied in another phase Ib trial including 21 treatment-naïve ALK-
positive NSCLC patients (28.6% with asymptomatic baseline brain
metastases, and 53% PD-L1 positive by SP142). Patients received in-
duction alectinib 600mg BID for 7 days (safety evaluation), followed by
alectinib 600mg BID in combination with atezolizumab 1200mg IV
q3w (expansion stage) until progression or unacceptable toxicity [117].
At a median follow up of 16.9 months, the RR, DoR and PFS was 86%,
20.3 and 21.7 months, respectively. Toxicity was again noteworthy,
with 66.7% grade 3 AEs (57.1% treatment-related, mainly rash and
liver toxicity) and 33% serious AEs, though no grade 4–5 AEs were
reported. Bearing in mind the impressive updated PFS of 34.8 months
results obtained with first-line alectinib in the phase III ALEX trial
[106], it does not seem that the combination of alectinib and atezoli-
zumab is adding any outcome advantage in this subgroup of patients.
Taking together all previous data, it is conceivable that combina-
tions of ALK inhibitors and ICI increase hepatotoxicity rates. Although
hepatotoxicity is a class-effect related to of ALK inhibitors, the me-
chanism of action for increased toxicity observed by combining both
treatments remains still unknown. Despite the discouraging above-
mentioned results, there are still several ongoing clinical trials testing
the efficacy and safety of combination strategies (NCT01998126,
NCT02511184, NCT02898116), however, to our knowledge,
preliminary results have not yet been reported.
ROS1 rearrangement
ROS1 rearrangements incidence in NSCLC range from 0.9 to 2%
and, as is the case of ALK-positive tumors, are associated with younger
age, never or light smoking history and adenocarcinoma histology
[118]. However, compared to ALK, ROS1-positive NSCLC patients have
different patterns of spread with significantly lower rate of extra-
thoracic metastasis including fewer brain metastasis during the course
of the disease [119]. So far crizotinib is the only ROS1 inhibitor ap-
proved by FDA and EMA [120,121], although there is cumulative data
suggesting that others such as ceritinib [122], entrectinib [123] or
lorlatinib [112], might be as well active in this oncogenic-driven dis-
ease.
Much less data exist for ROS1-positive NSCLC patients regarding its
immunophenotype. Although the high homology between ALK- and
ROS1- kinase domains might suggest a similar pre-clinical effect on PD-
L1 expression, high PD-L1 TPS in ROS1 has been rarely reported [36].
A retrospective Korean ROS1-positive cohort (n=12) treated with
ICIs, reported RR of 25% and median PFS and OS of 1.6 and
23.4 months respectively. The majority of patients presented lung
progression and data about PD-L1 expression was not reported [124]. In
the ImmunoTarget cohort, seven ROS1-positive NSCLC patients were
enrolled with RR of 17% but no data on PFS and OS was reported [35]
(Table 1). These results seem rather better than those reported with
durvalumab in ALK-positive NSCLC patients, and similar to that of wild-
type population.
RET fusion
RET is encoded by the proto-oncogene RET located at chromosome
10, and its oncogenic activation can occur by two primary mechanisms:
rearrangements and mutations, although only the latest has been de-
scribed in NSCLC (1–2% of lung adenocarcinomas and 14% in enriched
wild-type patients). In NSCLC, at least 12 fusion RET partners genes
have been identified, being the most common the KIF5B-RET found in
75% of cases [125]. RET-rearranged NSCLC tumours are potentially
sensitive to chemotherapy, particularly pemetrexed-based regimens. In
terms of prognostic value, RET-rearrangement does not significantly
correlates with OS and should not be considered a negative prognostic-
factor [125]. Two selective RET inhibitors show promise as new po-
tential standard strategies in RET-positive tumors; LOXO-292 [126] and
BLU-667 [127], both achieving RR beyond 60% in RET-positive NSCLC
patients.
PD-L1 expression (by E1L3N clone) is present in a substantial pro-
portion of RET-positive lung adenocarcinoma (42%, 25% and 21%
using TPS of ≥0%, 1–49% and 50%, respectively) [128] and the
median TMB (by NGS) is significantly lower (3.3 Mut/Mb) compared to
unselected NSCLC patients.
While PDL-1 is commonly expressed, responses to ICI, as observed
in other drivers, are poor. Recently, a small retrospective cohort
(n= 12) of RET-positive NSCLC patients treated with ICI, has reported
RR of 0% with a median DoR of 1.4 months, responses that were
otherwise not enriched by selecting those patients with positive PD-L1
expression or high TMB. Moreover, the median OS did not differ be-
tween those RET-positive patients exposed to ICI and those who did not
(18.2 vs. 17,9 months p=0.6) [129]. These results do not differ much
from those reported in the ImmunoTarget cohort (RR of only 6% and a
median PFS and OS of 2.1 and 21.3months, respectively) [35],
(Table 1). Therefore, thus far, ICI should not be offered as first-line
treatment in this population and RET-directed targeted therapy strate-
gies and platinum doublet chemotherapy should be considered prior to
any single-agent immunotherapy. It remains unknown however, whe-
ther the use of combinations of RET-selective inhibitors and ICI might
improve outcomes in this selected subset of patients.
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Conclusions
Although ICI has been a major breakthrough in lung cancer treat-
ment, the value on specific subsets of oncogenic driven tumors remains
uncertain. Overall, data from several trials and those reported in the
ImmunoTarget, point out towards the remarkably inferior activity of ICI
to that achieved with targeted agents in some oncogenic-driven tumors.
However, the very restricted number of patients evaluated and the little
information regarding biomarkers of immune-response such as TMB or
PDL-1, hamper the identification of the subgroup of patients, if any,
that might derive greater benefit from this therapeutic approach.
Combination of target therapies and ICI do not seem to improve out-
comes yet with a detrimental tolerability and an increased rate of
(hepatic) toxicity. As PD-L1 expression and an immune-suppressive
microenvironment are constitutive and not an adaptive feature of sev-
eral oncogenic-tumors, it is feasible that TMB may play a most relevant
role in oncogenic addicted tumors rather than PD-L1 expression itself,
however, it merits further evaluation in large prospective cohorts.
Further evaluation focusing on the study of biomarkers is needed in
this selected population of oncogenic-driven lung cancer patients to
identify those that might derive the greatest benefit. Meanwhile,
treatments with ICI in this subgroup of patients deserve careful con-
sideration and must be only used after exhaustion of other active tar-
geted treatments.
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